The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update

Critical Reviews in Toxicology

Volumn 44, Issue 10, 2014, Pages 895-913

  Idée, Jean Marc ^a   Fretellier, Nathalie ^a   Robic, Caroline ^a   Corot, Claire ^a  

^a Laboratoire Guerbet   (France)

Author keywords

Circulating fibrocytes; Contrast agents; Fibroblasts; Gadolinium; Gadolinium chelates; Kidney diseases; Magnetic resonance imaging; Nephrogenic systemic fibrosis; Transmetallation

Indexed keywords

CALDIAMIDE; GADOBENATE DIMEGLUMINE; GADOBENIC ACID; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM CHELATE; GADOLINIUM PENTETATE MEGLUMINE; GADOPENTETIC ACID; GADOTERATE MEGLUMINE; GADOTERIC ACID; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IMATINIB; LANTHANUM; LANTHANUM CARBONATE; UNCLASSIFIED DRUG; CHELATING AGENT; CONTRAST MEDIUM;

BIOACCUMULATION; CELL PROLIFERATION; COLLAGEN SYNTHESIS; CYTOKINE RELEASE; DISSOCIATION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG RELEASE; DRUG SAFETY; DRUG STABILITY; END STAGE RENAL DISEASE; ENZYME INHIBITION; FIBROBLAST; GLOMERULUS FILTRATION RATE; HUMAN; HYPEROSMOLALITY; HYPERPHOSPHATEMIA; METALLATION; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PHOSPHATE BLOOD LEVEL; REVIEW; RISK FACTOR; SYSTEMATIC REVIEW; THERMOSTABILITY; TRANSMETALLATION; ANIMAL; CHEMICALLY INDUCED; CHEMISTRY; DISEASE MODEL; FIBROSIS; PATHOLOGY;

ANIMALS; CHELATING AGENTS; CONTRAST MEDIA; DISEASE MODELS, ANIMAL; FIBROSIS; GADOLINIUM; HUMANS; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; RISK FACTORS;

EID: 84910037994     PISSN: 10408444     EISSN: 15476898     Source Type: Journal    
DOI: 10.3109/10408444.2014.955568     Document Type: Review

References (159)

1. Abraham JL, Thakral C, Skov L, Rossen K, Marckmann P. (2008). Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 158: 273-80.
2. Abu-Alfa AK. (2011). Nephrogenic systemic fibrosis and gadoliniumbased contrast agents. Adv Chronic Kidney Dis 18: 188-98.
3. ACR. (2013). Manual on Contrast Media. Version 9. Available at: http://www.acr.org/quality-safety/resources/~/media/37D84428BF1D4E1B 9A3A2918DA9E27A3.pdf/. Accessed on 8 September 2014.
4. Adding LC, Bannenberg GL, Gustafsson LE. (2001). Basic experimental studies and clinical aspects of gadolinium salts and chelates. Cardiovasc Drug Rev 19: 41-56.
5. Akimoto T, Kimura T, Watanabe Y, Ishikawa N, Iwazu Y, Saito O, et al. (2013). The impact of nephrectomy and renal transplantation on serum levels of soluble Klotho protein. Transplant Proc 45: 134-6.
6. Allen JA, Peterson A, Sufit R, Hinchcliff ME, Mahoney JM, Wood TA, et al. (2011). Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. Arthritis Rheum 63: 3633-9.
7. Anonymous. (2014). Long Term Retention of Gadolinium in Bone. ClinicalTrials.gov identifier: NCT01853163. Available at: http://www.clinicaltrials.gov/ct2/show/NCT01853163?termBONEgadolinium&rank1. (Accessed on 13 August 2014)
8. Barker-Griffith A, Goldberg J, Abraham JL. (2011). Ocular pathologic features and gadolinium deposition in nephrogenic systemic fibrosis. Arch Ophthalmol 129: 661-3.
9. Barton Pai A, Conner TA, McQuade CR. (2009). Therapeutic use of the phosphate binder lanthanum carbonate. Expert Opin Drug Metab Toxicol 5: 71-81.
10. Behets GJ, Verberckmoes SC, Oste L, Bervoets AR, Salom e M, Cox AG, et al. (2005). Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int 67: 1830-6.
11. Bennett CL, Qureshi ZP, Sartor AO, Norris LB, Murday A, Xirasagar S, Thomsen HS. (2012). Gadolinium-induced nephrogenic systemic fibrosis: the rise and fall of an iatrogenic disease. Clin Kidney J 5: 82-8.
12. Bernstein EJ, Isakova T, Sullivan ME, Chibnik LB, Wolf M, Kay J. (2014). Nephrogenic systemic fibrosis is associated with hypophosphataemia: a case-control-study. Rheumatology (Oxford) 53: 1613-7.
13. Bhagavathula N, Dame MK, DaSilva M, Jenkins W, Aslam MN, Perone P, Varani J. (2010). Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Invest Radiol 45: 769-77.
14. Bhagavathula N, DaSilva M, Aslam MN, Dame MK, Warner RL, Xu Y, Varani J, et al. (2009). Regulation of collagen turnover in human skin fibroblasts exposed to a gadolinium-based contrast agent. Invest Radiol 44: 433-9.
15. Bleavins K, Perone P, Naik M, Rehman M, Aslam MN, Dame MK, et al. (2012). Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biol Trace Elem Res 145: 257-67.
16. Boin F, Hummers LK. (2008). Scleroderma-like fibrosing disorders. Rheum Dis Clin North Am 34: 199-220.
17. Bonnemain B, Meyer D. (1985). Present Aspects of MRI Contrast Agents -Early Experience with DOTA Gadolinium. MR'85. Internationales Kernspintomographie Symposium; Garmisch Partenkirschen. 81-88.
18. (Abstract) Boyd AS, Zic JA, Abraham JL. (2007). Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56: 27-30.
19. Brambilla S, Valaperta S, Graziani G, Montanelli A. (2008). Gadolinium and lanthanum: an iatrogenic transmetallation? Clin Biochem 41: 1029-33.
20. Bucala R. (2008). Circulating fibrocytes: cellular basis for NSF. J Am Coll Radiol 5: 36-9.
21. Bucala R. (2012). Review Series - Infl ammation & Fibrosis. Fibrocytes and fibrosis. Q J Med 105: 505-8.
22. Cabella C, Crich SG, Corpillo D, Barge A, Ghirelli C, Bruno E, et al. (2006) Cellular labeling with Gd(III) chelates: only high thermodynamic stabilities prevent the cells acting as ' sponges ' of Gd 3 ions. Contrast Media Mol Imaging 1: 23-9.
23. Caravan P, Ellison JJ, McMurry TJ, Lauffer RB. (1999). Gadolinium(III) chelates as MRI contrast agents: structure, dynamics, and applications. Chem Rev 99: 2293-52.
24. Chachuat A, Molinier P, Bonnemain B, Chambon C, Gayet JL. (1992). Pharmacokinetics and tolerance of Gd-DOTA (Dotarem) in healthy volunteers and in patients with chronic renal failure. Eur Radiol 2: 326-9.
25. Chandran S, Petersen J, Jacobs C, Fiorentino D, Doeden K, Lafayette RA. (2009). Imatinib in the treatment of nephrogenic systemic fibrosis. Am J Kidney Dis 53: 129-32.
26. Christensen KN, Lee CU, Hanley MM, Leung N, Moyer TP, Pittelkow MR. (2011). Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 64: 91-6.
27. Cowper SE, Robin HS, Steinberg SM, Su LD, Gupta S, LeBoit PE. (2000). Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet 356: 1000-1001.
28. Cowper SE, Rabach M, Girardi M. (2008). Clinical and histological findings in nephrogenic systemic fibrosis. Eur J Radiol 66: 191-99.
29. Darrah TH, Prutsman-Pfeiffer JJ, Poreda RJ, Ellen Campbell M, Hauschka PV, Hannigan RE. (2009). Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics 1: 479-88.
30. DaSilva M, O'Brien Deming M, Fligiel SE, Dame MK, Johnson KJ, Swartz RD, Varani J. (2010). Responses of human skin in organ culture and human skin fibroblasts to a gadolinium-based MRI contrast agent: comparison of skin from patients with end-stage renal disease and skin from healthy subjects. Invest Radiol 45: 733-9.
31. De Broe ME. (2008). Can the risk of gadolinium be extrapolated to lanthanum? Semin Dial 21: 142-4.
32. Del Galdo F, Wermuth PJ, Addya S, Fortina P, Jimenez SA. (2010). NF ê B activation and stimulation of chemokine production in normal human macrophages by the gadolinium-based magnetic resonance contrast agent Omniscan: possible role in the pathogenesis of nephrogenic systemic fibrosis. Ann Rheum Dis 69: 2024-33.
33. Deng A, Martin DB, Spillane A, Chwalek J, St Surin-Lord S, Brooks S, et al. (2010). Nephrogenic systemic fibrosis with a spectrum of clinical and histopathological presentation: a disorder of aberrant dermal remodeling. J Cutan Pathol 37: 204-10.
34. D'Haese PC, Couttenye MM, Lamberts LV, Elseviers MM, Goodman WG, Schrooten I, et al. (1999). Aluminum, iron, lead, cadmium, copper, zinc, chromium, magnesium, strontium, and calcium content in bone of end-stage renal failure patients. Clin Chem 45: 1548-56.
35. Di Gregorio E, Gianolio E, Stefania R, Barutello G, Digilio G, Aime S. (2013). On the fate of MRI Gd-based contrast agents in cells. Evidence for extensive degradation of linear complexes upon endosomal internalization. Anal Chem 85: 5627-31.
36. Do C, Barnes JL, Tan C, Wagner B. (2014). Type of MRI contrast, tissue gadolinium, and fibrosis. Am J Physiol Renal Physiol 307: F844-55.
37. Doi S, Zou Y, Togao O, Pastor JV, John GB, Wang L, et al. (2011). Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem 286: 8655-65.
38. Drouven BJ, Evans CH. (1986). Collagen fibrillogenesis in the presence of lanthanides. J Biol Chem 261: 11792-7.
39. Edward M, Quinn JA, Mukherjee S, Jensen MB, Jardine AG, Mark PB, Burden AD. (2008). Gadodiamide contrast agent ' activates ' fibroblasts: a possible cause of nephrogenic systemic fibrosis. J Pathol 214: 584-93
40. Erratum in: J Pathol 214:593.
41. Edward M, Quinn JA, Burden AD, Newton BB, Jardine AG. (2010). Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology 256: 735-43.
42. Elmholdt TR, Pedersen M, J o rgensen B, Ramsing M, Olesen AB. (2011). Positive effect of low-dose imatinib mesylate in a patient with nephrogenic systemic fibrosis. Acta Derm Venereol 91: 478-9.
43. Emmez H, Kardes O, Dogulu F, Kurt G, Memis L, Baykaner MK. Role of antifibrotic cytokine interferon-gamma in the prevention of postlaminectomy peridural fibrosis in rats. (2008). Neurosurgery 62: 1351-7.
44. Errante Y, Cirimele V, Mallio CA, Di Lazzaro V, Zobel BB, Quattrocchi CC. (2014). Progressive increase of T1 signal intensity of the dentate nucleus on unenhanced magnetic resonance images is associated with cumulative doses of intravenously administered gadodiamide in patients with normal renal function, suggesting dechelation. Invest Radiol 49: 685-90.
45. European Medicine Agency. (2010). Assessment Report for Gadolinium- Containing Contrast Agents. Procedure No. EMEA/H/A-31/1097. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/gadolinium-31/WC500099538.pdf. Accessed on 12 August 2014.
46. Evans CH. Biochemistry of the Lanthanides. Biochemistry of the Elements. (1990). New York: Plenum Press, pp. 85-315.
47. Filopanti M, Corbetta S, Barbieri AM, Spada A. (2013) Pharmacology of the calcium sensing receptor. Clin Cases Miner Bone Metab 10: 162-5.
48. Food and Drug Administration. US Department of Health and Human Services. Center for Drug Evaluation and Research. Guidance for industry. (2005). Estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. http://www. fda.gov/downloads/Drugs/Guidances/UCM078932.pdf. Accessed on 13 August 2014.
49. Frenzel T, Lengsfeld P, Schirmer H, H u tter J, Weinmann HJ. (2008). Stability of gadolinium-based contrast agents in human serum at 37 C. Invest Radiol 43: 817-28.
50. Fretellier N, Idee JM, Guerret S, Hollenbeck C, Hartmann D, Gonzalez W, et al. (2011a). Clinical, biological, and skin histopathologic effects of ionic macrocyclic and nonionic linear gadolinium chelates in a rat model of nephrogenic systemic fibrosis. Invest Radiol 46: 85-93.
51. Fretellier N, Idee JM, Dencausse A, Karroum O, Guerret S, Poveda N, et al. (2011b). Comparative in vivo dissociation of gadolinium chelates in renally impaired rats: a relaxometry study. Invest Radiol 46: 292-300.
52. Fretellier N, Idee J, Bruneval P, Guerret S, Daubine F, Jestin G, et al. (2012). Hyperphosphataemia sensitizes renally impaired rats to the profibrotic effects of gadodiamide. Br J Pharmacol 165: 1151-62.
53. Fretellier N, Bouzian N, Parmentier N, Bruneval P, Jestin G, Factor C, et al. (2013). Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure. Toxicol Sci 131: 259-70.
54. Erratum in: Toxicol Sci 132:252.
55. Friman C, Storg ards E, Juvani M, Kock B. (1977). The glycosaminoglycans (mucopolysaccharides) in plasma in patients with renal insufficiency. Clin Nephrol 8: 435-9.
56. George SJ, Webb SM, Abraham JL, Cramer SP. (2010). Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol 163: 1077-81.
57. Girardi M, Kay J, Elston DM, Leboit PE, Abu-Alfa A, Cowper SE. (2011). Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. J Am Acad Dermatol 65: 1095-106.
58. Goddard DS, Magee CC, Lazar AJ, Miller DM. (2007). Nephrogenic fibrosing dermopathy with recurrence after allograft failure. J Am Acad Dermatol 56: S109-S11.
59. Goveia M, Chan BP, Patel PR. (2007). Evaluating the role of recombinant erythropoietin in nephrogenic systemic fibrosis. J Am Acad Dermatol 57: 725-7.
60. Grant D, Johnsen H, Juelsrud A, Lovhaug D. (2009). Effects of gadolinium contrast agents in na i ve and nephrectomized rats: relevance to nephrogenic systemic fibrosis. Acta Radiol 50: 156-169.
61. Grobner T. (2006). Gadolinium: a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104-8.
62. Erratum in: Nephrol Dial Transplant 21:1745.
63. Groves RW, Simpson KJ, Koblar S, Pitzalis C, Hay RJ. (1992). Tryptophan induced eosinophilia-myalgia syndrome: clinical and microscopic findings. J R Soc Med 85: 111-2.
64. Harrison A, Walker CA, Pereira KA, Parker D, Royle L, Pulukkody K, Norman TJ. (1993). Hepato-biliary and renal excretion in mice of charged and neutral gadolinium complexes of cyclic tetra-azaphosphinic and carboxylic acids. Magn Reson Imaging 11: 761-70.
65. Hashimoto S, Matsumoto K, Gon Y, Nakayama T, Takeshita I, Horie T. (1999). Hyperosmolarity-induced interleukin-8 expression in human bronchial epithelial cells through p38 mitogen-activated protein kinase. Am J Respir Crit Care Med 159: 634-40.
66. Haylor J, Dencausse A, Vickers M, Nutter F, Jestin G, Slater D, et al. (2010). Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Invest Radiol 45: 507-12.
67. Haylor J, Schroeder J, Wagner B, Nutter F, Jestin G, Idee JM, Morcos S. (2012). Skin gadolinium following use of MR contrast agents in a rat model of nephrogenic systemic fibrosis. Radiology 263: 107-16.
68. High WA, Ayers RA, Chandler J, Zito G, Cowper SE. (2007). Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21-6.
69. High WA, Ranville JF, Brown M, Punshon T, Lanzirotti A, Jackson BP. (2010). Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fl uorescence spectroscopy. J Am Acad Dermatol 62: 38-44.
70. Hill AB. (1965). The environment and disease: association or causation? Proc R Soc Med 58: 295-300.
71. Hirano S, Suzuki KT. (1996). Exposure, metabolism, and toxicity of rare earths and related compounds. Environ Health Perspect 104: 85-95.
72. Hope TA, High WA, Leboit PE, Chaopathomkul B, Rogut VS, Herfkens RJ, Brasch RC. (2009). Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 253: 390-8.
73. Hope TA, LeBoit P, High WA, Fu Y, Brasch RC. (2013). Evaluation of imatinib mesylate as a possible treatment for nephrogenic systemic fibrosis in a rat model. Magn Reson Imaging 31: 139-44.
74. Hutchinson AJ, Barnett ME, Krause R, Kwan JTC, Siami GA, on behalf of the SPD405-309 Lanthanum Study group. (2008). Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment. Nephron Clin Pract 110: c15-c23.
75. Id e e JM, Port M, Robic C, Medina C, Sabatou M, Corot C. (2009a). Role of thermodynamic and kinetic parameters in gadolinium chelate stability. J Magn Reson Imaging 30: 1249-58.
76. Idee JM, Port M, Dencausse A, Lancelot E, Corot C. (2009b). Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update. Radiol Clin North Am 47: 855-69
77. Jenkins W, Perone P, Walker K, Bhagavathula N, Aslam MN, DaSilva M, et al. (2011). Fibroblast response to lanthanoid metal ion stimulation: potential contribution to fibrotic tissue injury. Biol Trace Elem Res 144: 621-35.
78. Kanapilly GM. (1980). In vitro precipitation behavior of trivalent lanthanides. Health Phys 39: 343-6.
79. Kay J, High WA. (2008). Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 58: 2543-8.
80. Kanda T, Ishii K, Kawaguchi H, Kitajima K, Takenaka D. (2014). High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material. Radiology 270: 834-41.
81. Kelly B, Petitt M, Sanchez R. (2008). Nephrogenic systemic fibrosis is associated with transforming growth factor beta and Smad without evidence of renin-angiotensin system involvement. J Am Acad Dermatol 58: 1025-30.
82. Kurtkoti J, Snow T, Hiremagalur B. (2008). Gadolinium and nephrogenic systemic fibrosis: association or causation. Nephrology (Carlton) 13: 235-41.
83. Langer RD, Lorke DE, Neidl van Gorkom KF, Petroianu G, Azimullah S, Nurulain SM, et al. (2012). In an animal model nephrogenic systemic fibrosis cannot be induced by intraperitoneal injection of high-dose gadolinium based contrast agents. Eur J Radiol 81: 2562-7.
84. Laurent S, Vander Elst L, Copoix F, Muller RN. (2001). Stability of MRI paramagnetic contrast media: a proton relaxometric protocol for transmetallation assessment. Invest Radiol 36: 115-22.
85. Laurent S, Elst LV, Muller RN. (2006). Comparative study of the physicochemical properties of six clinical low molecular weight gadolinium contrast agents. Contrast Media Mol Imaging 1: 128-37.
86. Laurent S, Vander Elst L, Henoumont C, Muller RN. (2010). How to measure the transmetallation of a gadolinium complex. Contrast Media Mol Imaging 5: 305-8.
87. Li JX, Liu JC, Wang K, Yang XG. (2010). Gadolinium-containing bioparticles as an active entity to promote cell cycle progression in mouse embryo fibroblast NIH3T3 cells. J Biol Inorg Chem 15: 547-57.
88. Li JX, Fu LJ, Yang XG, Wang K. (2012). Integrin-mediated signaling contributes to gadolinium-containing-particle-promoted cell survival and G to S phase cell cycle transition by enhancing focal adhesion formation. J Biol Inorg Chem 17: 375-85.
89. MacNeil S, Bains S, Johnson C, Id e e JM, Factor C, Jestin G, et al. (2011). Gadolinium contrast agent associated stimulation of human fibroblast collagen production. Invest Radiol 46: 711-7.
90. Manjunath V, Perazella MA. (2011). Imaging patients with kidney disease in the era of NSF: can it be done safely? Clin Nephrol 75: 279-85.
91. Marckmann P, Skov L, Rossen K, Dupont A, Damholt MB, Heaf JG, Thomsen HS. (2006). Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359-62.
92. Marckmann P, Skov L, Rossen K, Heaf JG, Thomsen HS. (2007). Casecontrol study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22: 3174-8.
93. Martin DR, Semelka RC, Chapman A, Peters H, Finn PJ, Kalb B, Thomsen H. (2009). Nephrogenic systemic fibrosis versus contrastinduced nephropathy: risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J Magn Reson Imaging 30: 1350-6.
94. Messeguer A. (2011). Potential implication of aniline derivatives in the toxic oil syndrome (TOS). Chem Biol Interact 192: 136-41.
95. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. (2008). The bleomycin animal model: a useful tool to investigate treatment options for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol 40: 362-82.
96. Morcos SK. (2007). Nephrogenic systemic fibrosis following the administration of extracellular gadolinium based contrast agents: is the stability of the contrast agent molecule an important factor in the pathogenesis of this condition? Br J Radiol 80: 73-6.
97. Newton BB, Jimenez SA. (2009). Mechanism of NSF: New evidence challenging the prevailing theory. J Magn Reson Imaging 30: 1277-83.
98. Palasz A, Czekaj P. (2000) Toxicological and cytophysiological aspects of lanthanides action. Acta Biochim Pol 47: 1107-14.
99. Panesar M, Banerjee P, Barone GW. (2008). Clinical Improvement of nephrogenic systemic fibrosis after kidney transplantation. Clin Transplant 23: 803-8.
100. Perazella MA, Reilly RF. (2010). Imaging patients with kidney disease: how do we approach contrast-related toxicity? Am J Med Sci 341: 215-21.
101. Perone PA, Weber SL, DaSilva M, Paruchuri T, Bhagavathula N, Aslam MN, et al. (2010). Collagenolytic activity is suppressed in organ-cultured human skin exposed to a gadolinium-based MRI contrast agent. Invest Radiol 45: 42-8.
102. Pietsch H, Lengsfeld P, Steger-Hartmann T, Lo we A, Frenzel T, Hutter J, Sieber MA. (2009a). Impact of renal impairment on long-term retention of gadolinium in the rodent skin following the administration of gadolinium-based contrast agents. Invest Radiol 44: 226-33.
103. Pietsch H, Pering C, Lengsfeld P, Walter J, Steger-Hartmann T, Golfier S, et al. (2009b). Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study. J Magn Reson Imaging 30: 374-83.
104. Pietsch H, Raschke M, Ellinger-Ziegelbauer H, Jost G, Walter J, Frenzel T, et al. (2011a). The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Invest Radiol 46: 48-56.
105. Pietsch H, Jost G, Frenzel T, Raschke M, Walter J, Schirmer H, et al. (2011b). Efficacy and safety of lanthanoids as X-ray contrast agents. Eur J Radiol 80: 349-56.
106. Port M, Id e e JM, Medina C, Robic C, Sabatou M, Corot C. (2008). Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review. Biometals 21: 469-90.
107. Posada de la Paz M, Philen RM, Abaitua Borda I. (2001). Toxic oil syndrome: the perspective after 20 years. Epidemiol Rev 23: 231-47.
108. Prince MR, Zhang H, Morris M, MacGregor JL, Grossman ME, Silberzweig J, et al. (2008). Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 248: 807-16.
109. Rej RN, Holme KR, Perlin AS. (1990). Marked stereoselectivity in the binding of copper ions by heparin. Contrasts with the binding of gadolinium and calcium ions. Carbohydr Res 207: 143-52.
110. Riser BL, Bhagavathula N, Perone P, Garchow K, Xu Y, Fisher GJ, et al. (2012). Gadolinium-induced fibrosis is counter-regulated by CCN3 in human dermal fibroblasts: a model for potential treatment of nephrogenic systemic fibrosis. J Cell Commun Signal 6: 97-105.
111. Robic C, Catoen S, De Goltstein MC, Id e e JM, Port M. (2011). The role of phosphate on Omniscan( ® ) dechelation: an in vitro relaxivity study at pH 7. Biometals 24: 759-68. Erratum in: Biometals 24:769.
112. Rodby RA. (2011). Can gadolinium be given safely to a patient on dialysis? Semin Dial 24: 370-1.
113. Rofsky NM, Sherry AD, Lenkiski RE. (2008). Nephrogenic systemic fibrosis: a chemical perspective. Radiology 247: 608-11.
114. Rowe PSN, Hedge AM, Laurence JS, Lee SP, Brooks WM, McCarthy ET. (2010). Gadodiamide (Gd-OMN) binds circulating ASARM-peptides: a model for nephrogenic systemic fibrosis (NSF). American Society of Nephrology: Renal Week. Denver, CO, USA. J Am Soc Nephrol 21: abstract TH-FC069.
115. Saab G, Cheng S. (2007). Nephrogenic systemic fibrosis: a nephrologist's perspective. Hemodial Int 11: S2-S6.
116. Sachs F. (2010) Stretch-activated ion channels: what are they? Physiology (Bethesda) 25: 50-6.
117. Santhanam AV, D'Uscio LV, Peterson TE, Katusic ZS. (2008). Activation of endothelial nitric oxide synthase is critical for erythropoietininduced mobilization of progenitor cells. Peptides 29: 1451-5.
118. Sanyal S, Marckmann P, Scherer S, Abraham JL. (2011). Multiorgan gadolinium (Gd) deposition and fibrosis in a patient with nephrogenic systemic fibrosis - an autopsy-based review. Nephrol Dial Transplant 26: 3616-26.
119. Sato T, Ito K, Tamada T, Kanki A, Watanabe S, Nishimura H, et al. (2013). Tissue gadolinium deposition in renally impaired rats exposed to different gadolinium-based MRI contrast agents: evaluation with inductively coupled plasma mass spectrometry (ICP-MS). Magn Reson Imaging 31: 1412-7.
120. Schieren G, Gambichler T, Skrygan M, Burkert B, Altmeyer P, Rump LC, Kreuter A. (2010). Balance of profibrotic and antifibrotic [corrected] signaling in nephrogenic systemic fibrosis skin lesions. Am J Kidney Dis 55: 1040-9.
121. Schmidt-Lauber C, Bossaller L, Abujudeh HH, Vladimer GI, Christ A, Fitzgerald KA, et al. (2014). Gadolinium-based compounds induce NLRP3-dependent IL-1 â production and peritoneal infl ammation. Ann Rheum Dis (In press).
122. Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, et al. (2008). Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 3: 968-75.
123. Shen L, Yang A, Yao P, Sun X, Chen C, Mo C, et al. (2014). Gadolinium promoted proliferation in mouse embryo fibroblast NIH3T3 cells through Rac and PI3K/Akt signaling pathways. Biometals 27: 753-62.
124. Sieber MA, Pietsch H, Walter J, Haider W, Frenzel T, Weinmann HJ. (2008a). A preclinical study to investigate the development of nephrogenic systemic fibrosis: a possible role for gadolinium-based contrast media. Invest Radiol 43: 65-75.
125. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, et al. (2008b). Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 18: 2164-73.
126. Sieber MA, Lengsfeld P, Walter J, Schirmer H, Frenzel T, Siegmund F, et al. (2008c). Gadolinium-based contrast agents and their potential role in the pathogenesis of nephrogenic systemic fibrosis: the role of excess ligand. J Magn Reson Imaging 27: 955-62.
127. Siebert N, Xu W, Grambow E, Zechner D, Vollmar B. (2011). Erythropoietin improves skin wound healing and activates the TGF- â signaling pathway. Lab Invest 91: 1753-65.
128. Smythe WR, Alfrey AC, Craswell PW, Crouch CA, Ibels LS, Kubo H, et al. (1982). Trace element abnormalities in chronic uremia. Ann Intern Med 96: 302-10.
129. Soria JC, Blay JY, Spano JP, Pivot X, Coscas Y, Khayat D. (2011). Added value of molecular targeted agents in oncology. Ann Oncol 22: 1703-16.
130. Spencer AJ, Wilson SA, Batchelor J, Reid A, Pees J, Harpur E. (1997). Gadolinium chloride toxicity in the rat. Toxicol Pathol 25: 245-55.
131. Steger-Hartmann T, Raschke M, Riefke B, Pietsch H, Sieber MA, Walter J. (2009). The involvement of pro-infl ammatory cytokines in nephrogenic systemic fibrosis-a mechanistic hypothesis based on preclinical results from a rat model treated with gadodiamide. Exp Toxicol Pathol 61: 537-52.
132. Stratta P, Canavese C, Aime S. (2008). Gadolinium-enhanced magnetic resonance imaging, renal failure and nephrogenic systemic fibrosis/ nephrogenic fibrosing dermopathy. Curr Med Chem 15: 1229-35.
133. Swaminathan S, Ahmed I, McCarthy JT, Albright RC, Pittelkow MR, Caplice NM, et al. (2006). Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 145: 234-5.
134. Swaminathan S, Horn TD, Pellowski D, Abul-Ezz S, Bornhorst JA, Viswamitra S, Shah SV. (2007). Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 357: 720-2.
135. Swaminathan S, Shah SV. (2007). New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 18: 2636-43.
136. Swaminathan S, High WA, Ranville J, Horn TD, Hiatt K, Thomas M, et al. (2008). Cardiac and vascular metal deposition with high mortality in nephrogenic systemic fibrosis. Kidney Int 73: 1413-8.
137. Swaminathan S, Bose C, Shah SV, Hall KA, Hiatt KM. (2013). Gadolinium contrast agent-induced CD163( - ) ferroportin( - ) osteogenic cells in nephrogenic systemic fibrosis. Am J Pathol 183: 796-807.
138. Taupitz M, Stolzenburg N, Ebert M, Schnorr J, Hauptmann R, Kratz H, et al. (2013). Gadolinium-containing magnetic resonance contrast media: investigation on the possible transchelation of Gd(3 - ) to the glycosaminoglycan heparin. Contrast Media Mol Imaging 8: 108-16.
139. Thakral C, Abraham JL. (2009). Gadolinium-induced nephrogenic systemic fibrosis is associated with insoluble Gd deposits in tissues: in vivo transmetallation confirmed by microanalysis. Cutan Pathol 36: 1244-54.
140. Thomsen HS, Bennett CL. (2012). Six years after. Acta Radiol 53: 827-9.
141. Thomsen HS, Morcos SK, Almen T, Bellin MF, Bertolotto M, Bongartz G, et al. (2013). Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines. Eur Radiol 23: 307-18.
142. Tweedle MF, Wedeking P, Kumar K. (1995). Biodistribution of radiolabeled, formulated gadopentetic acid, gadoteridol, gadoteric acid, and gadodiamide in mice and rats. Invest Radiol 30: 372-80.
143. Varani J, DaSilva M, Warner RL, Deming MO, Barron AG, Johnson KJ, Swartz RD. (2009). Effects of gadolinium-based magnetic resonance imaging contrast agents on human skin in organ culture and human skin fibroblasts. Invest Radiol 44: 74-81.
144. Vercruysse KP, Li H, Luo Y, Prestwich GD. (2002). Thermosensitive lanthanide complexes of hyaluronan. Biomacromolecules 3: 639-43.
145. Vidaud C, Bourgeois D, Meyer D. (2012). Bone as target organ for metals: the case of f-elements. Chem Res Toxicol 25: 1161-75.
146. Wadas TJ, Sherman CD, Miner JH, Duncan JR, Anderson CJ. (2010). The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. Magn Reson Med 64: 1274-80.
147. Wagner B, Tan C, Barnes JL, Ahuja S, Davis TL, Gorin Y, Jimenez F. (2012). Nephrogenic systemic fibrosis: evidence for oxidative stress and bone marrow-derived fibrocytes in skin, liver, and heart lesions using a 5/6 nephrectomy rodent model. Am J Pathol 181: 1941-52.
148. Wang Y, Alkasab TK, Narin O, Nazarian RM, Kaewlai R, Kay J, et al. (2011). Incidence of nephrogenic systemic fibrosis after adoption of restrictive gadolinium-based contrast agent guidelines. Radiology 260: 105-11.
149. Wasserman AJ, Monticello TM, Feldman RS, Gitlitz PH, Durham SK. (1996). Utilization of electron probe microanalysis in gadoliniumtreated mice. Toxicol Pathol 24: 588-94.
150. Wedeking P, Kumar K, Tweedle MF,. (1993). Dose-dependent biodistribution of [153Gd]Gd(acetate)n in mice. Nucl Med Biol 20: 679-91.
151. Wermuth PJ, Del Galdo F, Jimenez SA. (2009). Induction of the expression of profibrotic cytokines and growth factors in normal human peripheral blood monocytes by gadolinium contrast agents. Arthritis Rheum 60: 1508-18.
152. Wermuth PJ, Jimenez SA. (2012a). Gadolinium compounds signaling through TLR4 and TLR7 in normal human macrophages: establishment of a proinfl ammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis. J Immunol 189: 318-27.
153. Wermuth PJ, Jimenez SA. (2012b). Intratracheal instillation of Omniscan in an adenine-induced model of chronic renal failure. A new model of nephrogenic systemic fibrosis. Arthr Rheum 64: s974 (abstract).
154. Wermuth PJ, Jimenez SA. (2014). Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: comparison of linear and macrocyclic agents. Clin Exp Immunol 175: 113-25.
155. White GW, Gibby WA, Tweedle MF. (2006). Comparison of Gd(DTPABMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. Invest Radiol 41: 272-8.
156. Wollanka H, Weidenmaier W, Giersig C. (2009). NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transplant 24: 3882-4.
157. Wong J. (2012). Gadolinium prescribing trends. The effect of regulatory action. Pharmacoepidemiol Drug Saf (Suppl 3): 462-3 (abstract).
158. Xia D, Davis RL, Crawford JA, Abraham JL. (2010). Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. Acta Radiol 51: 1126-36.
159. Yang L, Krefting I, Gorovets A, Marzella L, Kaiser J, Boucher R, Rieves D. (2012). Nephrogenic systemic fibrosis and class labeling of gadolinium-based contrast agents by the Food and Drug Administration. Radiology 265: 248-53.